Skip to main content
Erschienen in: Clinical Rheumatology 5/2019

12.04.2019 | Editorial

Think autoimmunity, breath autoimmunity, and learn autoimmunity

verfasst von: Elias Toubi, Zahava Vadasz

Erschienen in: Clinical Rheumatology | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Excerpt

The 11th international congress on autoimmunity organized by Prof Yehuda Shoenfeld in Lisbon on May 2018 was a great celebration for auto-immunologists. More than 2000 participants from the entire world shared their views on the various aspects of autoimmunity, presented updates on issues such as pathogenesis, diagnosis, and new therapeutic approaches. The current volume of Clinical Rheumatology contains some of the presentations from this fascinating meeting, emphasizing how autoimmunity is indeed complex.
1.
Dendritic cells: The role of dendritic cells (DCs) in handling antigens, including auto-antigens, is considered to be a critical phase in the pathogenesis of many immune-mediated and autoimmune diseases. In his review, Slobodin G. discusses the role of DCs in the pathogenesis of ankylosing spondylitis (AS) [1]. The review focuses on the role of DCs in the initiation of immune-mediated inflammation by increasing the production of pro-inflammatory cytokines such as IL-17. In this respect, the ability of DCs in stimulating CD4 T cells is dependent in part on the proper engagement of HLA-B27 with the co-stimulatory molecule CD86. When monocyte-derived CD14-CD40+HLA DR+CD86+DCs from HLA-B27+ patients with spondyloarthritis were assessed, they were found to have a markedly decreased capacity to stimulate T cells when compared with healthy controls. In this respect, both splenic DCs of HLA B27 transgenic rats and monocyte-derived DCs of patients with AS have demonstrated significantly lower baseline expression of class II MHC molecules. Of importance to mention, that HLA B27, normally composed of a heavy chain connected to β2-microglobulin, was shown to form abnormal heavy chain homodimers on the surface of activated DCs. These have been shown to bind to different groups of immune receptors when compared with classical HLA B27 molecule, mainly KIR (killer cell immunoglobulin-like receptor) 3DL2 receptor expressed by natural killer cells (NK) and NK T cells. Ligation to HLA B27 heavy chain homodimer through KIR3DL2 has led to expansion of the pool of KIR3DL2 bearing cells as well as diminished interferon (IFN)-γ production. In similarity with many immune cells and regulatory proteins, DCs change their phenotype depending on the state of activation and migration. Dendritic cells possess plasticity features, and depending on stimulatory conditions or cytokine milieu, they can undergo transformation and acquire stimulatory properties on one hand but a tolerogenic profile on the other [2, 3].
 
2.
The association between viral infections or malignancy and autoimmune diseases: In a paper by N. Mahroum et al. the association between rheumatoid arthritis (RA) and chronic hepatitis B viral infection (HBV) was assessed, assuming that hepatitis viruses may play a role in the pathogenesis of RA. Patients with RA were compared with age and sex-matched controls regarding the proportion of HBV infection in a case-control study. The study was performed utilizing the medical database of Clalit Health Services. HBV infection was found to be significantly higher in RA patients compared with controls. The study indicates that viruses may contribute to the pathogenesis of autoimmune diseases and to the production of a wide range of autoantibodies [4]. Rheumatologists should improve screening and control of viruses such as HBV, HCV, and others in patients with autoimmune diseases, mainly those planned to receive immune suppressive drugs and biological agents such as anti-TNF [5]. In another paper, S. Deshayes et al. reported on the increased prevalence of malignancy in patients suffering from giant cell arteritis (GCA). Forty-nine observations of malignancies in GCA patients were followed. Solid neoplasms were reported in 33 (67%) and malignant blood diseases in 16 (33%). Diagnosis of GCA and malignancy was synchronous in 7 (14%). The authors suggest that initial follow-up dictated by vasculitis may have led to an early identification of associated malignancy. The issue of malignancy in patients with autoimmune diseases and or related to long-term therapy with immune suppressive agents should remain under investigation [6].
 
3.
Rare clinical aspects in autoimmune diseases: Congenital anomalies should be considered and looked for in pregnant women with SLE. M. Sousa et al. evaluated the performance of the first trimester combined screening in patients with SLE, aiming to assess the influence of pregnancy in SLE women on biochemical parameters mainly on serum chorionic gonadotropin hormone (hCG) and whether this may give an increased rate of false positivity during the first trimester. The finding of high total serum hCG values in pregnant women with a pre-existing autoimmune disease should raise a suspicion of false positive results. Correction factors should be calculated and entered in the risk algorithm, in order to avoid the rise in the number of false-positive results and consequently the overuse of invasive methods [7]. The association between cryoglobulinemia and malignancy was discussed by Tocut et al. by reporting on a case of 40 years old woman, who developed nephritic syndrome and acute renal failure 2 weeks post-partum. She harbored type I and type II cryoglobulinemia approved by renal and cutaneous biopsies. Monoclonal gammopathy of undetermined source (MGUS) was documented following a bone marrow biopsy. Despite therapy with cyclophosphamide, rituximab, plasmapheresis, and dialysis, the patient died after 8 months. It seems that an overlapping entity of type I and II cryoglobulinemia with severe multi-organ involvement is rare and usually resistant to most available therapies and is fatal [8]. Immune checkpoint inhibitor (ICI)-induced myositis is a newly emerging systemic inflammatory myopathy following the administration of ICI. In the report by Kadota H. et al. the authors review 15 cases of ICI-induced myositis, mostly developing in patients with melanoma following the treatment with anti-PD-1 alone and anti-CTLA-4 alone or the combination of both. Seven of these patients died due to myocarditis, in two due to respiratory muscle paralysis and cancer progression in two. The introduction of ICI therapy is a revolutionary approach of treatment which improved the survival of advanced melanoma. On the other hand, ICI-induced myopathies are considered to be a major cause of severe morbidity and mortality the prevalence of which should be recorded [9, 10].
 
Literatur
2.
Zurück zum Zitat Prajzlerova K, Grobelna K, Pavelka K, Senolt L, Filkova M (2016) An update on biomarkers in axial spondyloarthritis. Autoimmun Rev 15:501–509CrossRefPubMed Prajzlerova K, Grobelna K, Pavelka K, Senolt L, Filkova M (2016) An update on biomarkers in axial spondyloarthritis. Autoimmun Rev 15:501–509CrossRefPubMed
3.
Zurück zum Zitat Garcia-Gonzalez P, Ubilla-Olguin G, Catalan D, Schinnerling K, Aguillon JC (2016) Tolerogenic dendritic cells for reprogramming of lymphocyte responses in autoimmune diseases. Autoimmun Rev 15:1071–1080CrossRefPubMed Garcia-Gonzalez P, Ubilla-Olguin G, Catalan D, Schinnerling K, Aguillon JC (2016) Tolerogenic dendritic cells for reprogramming of lymphocyte responses in autoimmune diseases. Autoimmun Rev 15:1071–1080CrossRefPubMed
5.
Zurück zum Zitat Kobie JJ, Zheng B, Bryk P, Barnes M, Ritchlin CT, Tabechian DA, Anandarajah AP, Looney RJ, Thiele RG, Anolik JH, Coca A, Wei C, Rosenberg AF, Feng C, Treanor JJ, Lee FE, Sanz I (2011) Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor. Arthritis Res Ther 13:R209CrossRefPubMedPubMedCentral Kobie JJ, Zheng B, Bryk P, Barnes M, Ritchlin CT, Tabechian DA, Anandarajah AP, Looney RJ, Thiele RG, Anolik JH, Coca A, Wei C, Rosenberg AF, Feng C, Treanor JJ, Lee FE, Sanz I (2011) Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor. Arthritis Res Ther 13:R209CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Deshayes S, Liozon E, Chanson N, Sacre K, Moulinet T, Blanchard-Delaunay C, Espitia O, Versini M, Le Gallou T, Kahn JE, Grobost V, Humbert S, Samson M, Mourot Cottet R, Mazodier K, Dartevel A, Campagne J, Dumont A, Bienvenu B, Lambert M, Daumas A, Saadoun D, Aouba A, de Boysson H (2018) Concomitant association of giant cell arteritis and malignancy: a multicenter retrospective case-control study. Clin Rheumatol. https://doi.org/10.1007/s10067-018-04407-y Deshayes S, Liozon E, Chanson N, Sacre K, Moulinet T, Blanchard-Delaunay C, Espitia O, Versini M, Le Gallou T, Kahn JE, Grobost V, Humbert S, Samson M, Mourot Cottet R, Mazodier K, Dartevel A, Campagne J, Dumont A, Bienvenu B, Lambert M, Daumas A, Saadoun D, Aouba A, de Boysson H (2018) Concomitant association of giant cell arteritis and malignancy: a multicenter retrospective case-control study. Clin Rheumatol. https://​doi.​org/​10.​1007/​s10067-018-04407-y
9.
Zurück zum Zitat Kadota H, Gono T, Shirai Y, Okazaki Y, Takeno M, Kuwana M (2018) Immune checkpoint inhibitor-induced myositis: a case report and literature review. Clin Rheumatol Kadota H, Gono T, Shirai Y, Okazaki Y, Takeno M, Kuwana M (2018) Immune checkpoint inhibitor-induced myositis: a case report and literature review. Clin Rheumatol
10.
12.
Zurück zum Zitat Watad A, Amital H, Aljadeff G, Zandman-Goddard G, Orbach H, Shoenfeld Prolactin Y (2016) Another important player in the mosaic of autoimmunity. Isr Med Assoc J 18:542–543PubMed Watad A, Amital H, Aljadeff G, Zandman-Goddard G, Orbach H, Shoenfeld Prolactin Y (2016) Another important player in the mosaic of autoimmunity. Isr Med Assoc J 18:542–543PubMed
13.
Zurück zum Zitat Jara LJ, Medina G, Saavedra MA, Vera-Lastra O, Torres-Aguilar H, Navarro C, Vazquez DM, Espinoza LR (2017) Prolactin has a pathogenic role in systemic lupus erythematosus. Immun Res 65:512–523CrossRef Jara LJ, Medina G, Saavedra MA, Vera-Lastra O, Torres-Aguilar H, Navarro C, Vazquez DM, Espinoza LR (2017) Prolactin has a pathogenic role in systemic lupus erythematosus. Immun Res 65:512–523CrossRef
15.
Zurück zum Zitat Levy Y, Ruhrman-Shahar N (2016) The ongoing debate regarding long-term safety of silicone breast augmentation rages. Isr Med Assoc J 18:754–755PubMed Levy Y, Ruhrman-Shahar N (2016) The ongoing debate regarding long-term safety of silicone breast augmentation rages. Isr Med Assoc J 18:754–755PubMed
16.
Zurück zum Zitat Lakota K, Perdan-Piskmajer K, Sodin-Semrl S, Gucnik S, Subelj V, Prosenc K, Mrak Poljsak K, Tomsic M, Ambrozic A, Praprotnik S (2018) The immunogenicity of seasonal and pandemic influenza vaccination in autoimmune inflammatory rheumatic patients—a 6-month follow-up prospective study. Clin Rheumatol. https://doi.org/10.1007/s10067-019-04439-y Lakota K, Perdan-Piskmajer K, Sodin-Semrl S, Gucnik S, Subelj V, Prosenc K, Mrak Poljsak K, Tomsic M, Ambrozic A, Praprotnik S (2018) The immunogenicity of seasonal and pandemic influenza vaccination in autoimmune inflammatory rheumatic patients—a 6-month follow-up prospective study. Clin Rheumatol. https://​doi.​org/​10.​1007/​s10067-019-04439-y
17.
Zurück zum Zitat Colafrancesco S, Perricone C, Shoenfeld Y (2016) Autoimmune/inflammatory syndrome induced by adjuvants and Sjogren’s syndrome. IsrMed Assoc J 18:150–153 Colafrancesco S, Perricone C, Shoenfeld Y (2016) Autoimmune/inflammatory syndrome induced by adjuvants and Sjogren’s syndrome. IsrMed Assoc J 18:150–153
18.
19.
Zurück zum Zitat Mahler M, Meroni PL, Andrade LE, Khamashta M, Bizzaro N, Casiano CA, Fritzler MJ (2016) Towards a better understanding of the clinical association of anti-DFS70 autoantibodies. Autoimmun Rev 15:198–201CrossRefPubMed Mahler M, Meroni PL, Andrade LE, Khamashta M, Bizzaro N, Casiano CA, Fritzler MJ (2016) Towards a better understanding of the clinical association of anti-DFS70 autoantibodies. Autoimmun Rev 15:198–201CrossRefPubMed
20.
Zurück zum Zitat Rigon A, Infantino M, Merone M, Iannello G, Tincani A, Cavazzana I, Carabellese N, Radice A, Manfredi M, Soda P, Afeltra A (2017) The inter-observer reading variability in anti-nuclear antibodies indirect (ANA) immunofluorescence test: a multicenter evaluation and review of the literature. Autoimmun Rev 16:1224–1229CrossRefPubMed Rigon A, Infantino M, Merone M, Iannello G, Tincani A, Cavazzana I, Carabellese N, Radice A, Manfredi M, Soda P, Afeltra A (2017) The inter-observer reading variability in anti-nuclear antibodies indirect (ANA) immunofluorescence test: a multicenter evaluation and review of the literature. Autoimmun Rev 16:1224–1229CrossRefPubMed
23.
Zurück zum Zitat Favalli EG, Raimondo MG, Becciolini A, Crotti C, Biggioggero M, Caporali R (2017) The management of first line biologic therapy failures in rheumatoid arthritis: current practice and future perspectives. Autoimmun Rev 16:1185–1195CrossRefPubMed Favalli EG, Raimondo MG, Becciolini A, Crotti C, Biggioggero M, Caporali R (2017) The management of first line biologic therapy failures in rheumatoid arthritis: current practice and future perspectives. Autoimmun Rev 16:1185–1195CrossRefPubMed
Metadaten
Titel
Think autoimmunity, breath autoimmunity, and learn autoimmunity
verfasst von
Elias Toubi
Zahava Vadasz
Publikationsdatum
12.04.2019
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 5/2019
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-019-04540-2

Weitere Artikel der Ausgabe 5/2019

Clinical Rheumatology 5/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.